«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《国际消化病杂志》[ISSN:1673-534X/CN:31-1953/R]

期数:

2024年03期

页码:

160-164

栏目:

论著

出版日期:

2024-06-25

文章信息/Info

Title:

Clinical value of serum CCL16 in prognosis prediction of patients with decompensated hepatitis B cirrhosis

作者:

田婉婷; 吴光辉; 王超智

723000 陕西汉中，三二〇一医院消化内科

Author(s):

TIAN Wanting; WU Guanghui; WANG Chaozhi

Department of Gastroenterology,3201 Hospital, Hanzhong 723000, China

关键词:

CC趋化因子配体16 ; 乙型肝炎肝硬化; 失代偿期; 预后; 临床价值

Keywords:

Chemokine CC motif ligand 16;  Hepatitis B cirrhosis;  Decompensation;  Prognosis; Clinical value

分类号:

-

DOI:

10.3969/j.issn.1673-534X.2024.03.005

文献标识码:

-

摘要:

目的探讨血清CC趋化因子配体16（CCL16）对乙型肝炎肝硬化失代偿期患者预后预测的临床价值。方法选择2021年9月至2022年9月三二〇一医院收治的100例乙型肝炎肝硬化失代偿期患者作为研究对象。根据Child-Pugh评分及分级标准，将患者分为Child-PughA级组（n＝30）、Child-PughB级组（n＝38）、Child-PughC级组（n＝32）；根据随访6个月的预后情况，将患者分为生存组（n＝58）和死亡组（n＝42）。比较各组血清CCL16水平及相关指标；采用logistic回归模型分析探讨影响乙型肝炎肝硬化失代偿期患者预后的因素；采用ROC曲线分析血清CCL16对乙型肝炎肝硬化失代偿期患者预后的预测效能。结果Child-PughA级组、Child-PughB级组、Child-PughC级组的血清CCL16水平依次降低，差异有统计学意义（P＜0.05）。与生存组相比，死亡组的白细胞计数、HBV-DNA、总胆红素（TBil）水平、Child-Pugh评分均显著升高，血清CCL16水平显著降低（P均＜0.05）。多因素logistic回归模型分析结果显示，血清CCL16、白细胞计数、HBV-DNA、TBil、Child-Pugh评分均是乙型肝炎肝硬化失代偿期患者预后的影响因素（P均＜0.05）。ROC曲线分析结果显示，血清CCL16预测乙型肝炎肝硬化失代偿期患者预后的曲线下面积（AUC）为0.921，特异度为97.62%，敏感度为74.14%。结论血清CCL16水平与乙型肝炎肝硬化失代偿期患者的病情严重程度及预后密切相关，其随着患者病情严重程度的加重而显著降低，并且其对患者预后的预测效能较高。

Abstract:

Objective This paper intends to explore the clinical value of serum chemokine CC motif ligand 16 (CCL16) in predicting the prognosis of patients with decompensated hepatitis B cirrhosis. Methods? A hundred patients with decompensated hepatitis B cirrhosis admitted to 3201 Hospital from September 2021 to September 2022 were selected as the study subjects. According to the Child-Pugh score and grading criteria, the patients were divided into the Child-Pugh A group (n＝30), the Child-Pugh B group (n＝38), and the Child-Pugh C group (n＝32). Based on the 6-month follow-up prognosis, the patients were assigned into the survival group (n＝58) and the death group (n＝42). The serum CCL16 levels and other related indicators of each group were compared. The logistic regression analysis was conducted to explore the factors affecting the prognosis of patients with decompensated hepatitis B cirrhosis. The ROC curve analysis was performed to predict the prognostic efficacy of serum CCL16 in patients with decompensated hepatitis B cirrhosis. Results? The serum CCL16 levels in the Child-Pugh A group, the Child-Pugh B group, and the Child-Pugh C group decrease sequentially, with a statistically significant difference (P＜0.05). Compared with the survival group, the white blood cell count, the HBV-DNA, the TBil level, and the Child-Pugh score are significantly increased, while the serum CCL16 level is significantly decreased (P＜0.05). The results of multivariate logistic regression analysis shows that the serum CCL16, the white blood cell count, the HBV-DNA, the TBil level, and the Child-Pugh scores are influencing factors for the prognosis of patients with decompensated hepatitis B cirrhosis (P＜0.05). The ROC curve analysis indicates that the area under the curve (AUC) of serum CCL16 predicting the prognosis of patients with decompensated hepatitis B cirrhosis is 0.921, with a specificity of 97.62% and a sensitivity of 74.14%. Conclusions? The serum CCL16 level is closely related to the severity and prognosis of patients with decompensated hepatitis B cirrhosis. It significantly decreases with the severity of the patient's condition, and its predictive power for patient prognosis is high.

参考文献/References

1 Zhao H, Wang Q, Luo C, et al. Recompensation of decompensated hepatitis B cirrhosis: Current status and challenges[J]. Biomed Res Int, 2020, 2020: 9609731.
2van Kleef LA, Choi HSJ, Brouwer WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B[J]. JHEP Rep, 2021, 3(5): 100350.
3Cheng HY, Lin HC, Lin HL, et al. Association between nonselective beta-blocker use and hepatocellular carcinoma in patients with chronic hepatitis B without cirrhosis and decompensation[J]. Front Pharmacol, 2022, 12: 805318.
4Wu Q, Mao W. New prognostic factor for hepatitis B virus-related decompensated cirrhosis: Ratio of monocytes to HDL-cholesterol[J]. J Clin Lab Anal, 2021, 35(11): e24007.
5Lee HM, Banini BA. Updates on chronic HBV: current challenges and future goals[J]. Curr Treat Options Gastroenterol, 2019, 17(2):271-291
6Demirtas CO, D'Alessio A, Rimassa L, et al. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma[J]. JHEP Rep, 2021, 3(5): 100347.
7 杜艳妮, 吕志彬, 关春爽, 等. 钆塞酸二钠增强MRI功能性肝脏影像评分影像征象与Child-Turcotte-Pugh分级评估肝功能的对照研究[J]. 临床放射学杂志, 2021, 40(11): 2134-2138.
8Shen W, Zhang X, Tang J, et al. CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis[J]. Theranostics, 2021, 11(5): 2297-2317.
9Weiergr?ber OH, Petrovi? D, Kislat A, et al. Structure and dynamics of human chemokine CCL16-implications for biological activity[J]. Biomolecules, 2022, 12(11): 1588.
10 García-Pagán JC, Saffo S, Mandorfer M, et al. Where does TIPS fit in the management of patients with cirrhosis?[J]. JHEP Rep, 2020, 2(4):100122.
11 王贵强, 王福生, 庄辉, 等. 慢性乙型肝炎防治指南（2019年版） [J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669.
12 Huang X, Yan M, Deng Z, et al. Natural history of decompensated cirrhosis with serum hepatitis B DNA ＜ 2 000 IU/mL: a retrospective study[J]. BMC Gastroenterol, 2022, 22(1): 452.
13 Ye J, Huang Y, Sun Y, et al. Dynamic monitoring with shear wave elastography predicts outcomes of chronic hepatitis B patients with decompensated cirrhosis[J]. Ann Transl Med, 2021, 9(21): 1613.
14 Gao F, Li X, Wan G, et al. Development and external validation of a prognostic nomogram for acute decompensation of chronic hepatitis B cirrhosis[J]. BMC Gastroenterol, 2018, 18(1): 179.
15 Korbecki J, Kojder K, Barczak K, et al. Hypoxia alters the expression of CC chemokines and CC chemokine receptors in a tumor-A literature review[J]. Int J Mol Sci, 2020, 21(16): 5647.
16 Neves F, Abrantes J, Lopes AM, et al. Evolution of CCL16 in glires (rodentia and lagomorpha) shows an unusual random pseudogenization pattern[J]. BMC Evol Biol, 2019, 19(1): 59.
17 Hayatbakhsh MM, Gowhari Shabgah A, Pishgouyi S, et al. The serum levels of CCL2 and CCL16 expression in patients with irritable bowel syndrome[J]. Rep Biochem Mol Biol, 2019, 8(1): 9-14.
18 Paksoy ZB, Cayonu M, Yucel C, et al. The treatment efficacy of nasal polyposis on olfactory functions, clinical scoring systems and inflammation markers[J]. Eur Arch Otorhinolaryngol, 2019, 276(12):3367-3372.
19 She S, Ren L, Chen P, et al. Functional roles of chemokine receptor CCR2 and its ligands in liver disease[J]. Front Immunol, 2022, 13:812431.
20 Zhuo JY, Lu D, Lin ZY, et al. CC motif chemokine ligand 16 inhibits the progression of liver cirrhosis via inactivating hepatic stellate cells[J]. Hepatobiliary Pancreat Dis Int, 2020, 19(5): 440-448.
21 Cheng JH, Yip CW, Jiang YK, et al. Clinical predictors impacting cryptococcal dissemination and poor outcome in patients with cirrhosis[J]. Open Forum Infect Dis, 2021, 8(7): ofab296.
22 唐淬蓉, 胡承光, 周宇辰, 等. 乙型肝炎肝硬化合并糖尿病时发生肝细胞癌的风险：一项随访5年的前瞻性队列研究[J]. 南方医科大学学报, 2021, 41(3): 313-318.
23 崔丽娜, 王秀芳, 孙瑞青, 等. 自体外周血干细胞回输对失代偿期肝硬化患者远期预后影响的研究[J]. 中华肝脏病杂志, 2022, 30(3): 279-284.

备注/Memo

备注/Memo:

-

常用功能

更新日期/Last Update: 2024-06-25